Increase in Lead Levels Linked to Worse School Academic Performance
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 4, 2025 -- A 1-unit increase in lead levels is associated with worse academic performance throughout school grades, according to a study published online May 28 in JAMA Network Open.
George L. Wehby, M.P.H., Ph.D., from the University of Iowa in Iowa City, examined the association of a 1-unit change in early childhood blood lead levels below 3.5 µg/dL versus ≥3.5 µg/dL with academic achievement in a cohort study that linked birth certificates of children born from 1989 to 2010 with their math and reading test scores for grades 2 through 11 and to their early childhood blood lead testing data.
Up to 305,256 children and 1,782,873 child-grade observations were included in the analytical sample. Wehby found that at a mean child age at lead testing of 1.9 years, 37.7 percent of children had lead values below 3.5 µg/dL. A 1-unit increase in lead levels below 3.5 µg/dL was associated with lower national percentile rank (NPR) scores in math and reading (by −0.47 and −0.38, respectively). For lead levels ≥3.5 µg/dL, a 1-unit increase was also associated with lower NPR scores in math and in reading (−0.52 and −0.56, respectively). Across grades 2 through 11, the declines in these scores were persistent.
"Reconsidering and potentially lowering current blood lead reference values for intervention may be needed to better address the associations of low-level lead exposures with cognitive and academic outcomes," Wehby writes.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-06-05 06:00
Read more

- Fido Might Protect Your Baby Against Eczema
- Salmonella Outbreak Triggers Egg Recall in 9 States
- This Easier-To-Follow Diet Might Help IBS Patients, Study Says
- Shorter Leukocyte Telomere Length Linked to Higher Incidence of Age-Related Brain Diseases
- Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
- Ex-White House Doctor Says Biden Should Have Had a Cognitive Test
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions